For anyone in Pau looking to source CJC-1295, the first thing to know is that this compound is available only through an online research supply market. This concentration of supply in online vendors is ultimately a quality advantage — top vendors distinguish themselves through rigorous testing in ways brick-and-mortar outlets simply cannot. What reliably differentiates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety documentation. This guide gives Pau researchers the framework to assess vendor quality rigorously and source verified-quality CJC-1295 with confidence.
The Science Behind CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Pau studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
CJC-1295 Purchasing Guide
Before looking at individual vendors, build a clear picture of what a proper COA looks like — so you can recognise whether a vendor meets it. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone cannot verify molecular identity. Strong quality indicators beyond COA quality: established track record of at least two years, customer service that can discuss analytical methods, and temperature-appropriate packaging with desiccant. For Pau researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, begin with a small order, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Pau
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the safety data available for CJC-1295 is based on academic studies rather than pharmaceutical approval data. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; avoid repeatedly thawing and refreezing reconstituted peptide by dividing into single-dose aliquots before freezing. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results reported in endotoxin units per mg or mL and confirm they fall within appropriate thresholds. The research literature on CJC-1295 should be studied thoroughly before designing any protocol — study methodologies, dosing, and endpoints vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
